

CHINA MEDICAL (INTERNATIONAL) GROUP LIMITED

(Company Registration No. 200505118M)

THIRD SUPPLEMENTAL AGREEMENT TO THE LOAN AGREEMENT RELATING TO THE LOAN OF HK\$20,000,000 GRANTED TO THE COMPANY'S SUBSIDIARY

Unless otherwise defined herein, all capitalised terms used in this announcement shall have the same meanings as defined in the announcements released on 20 June 2016, 13 December 2016 and 29 March 2017 in respect of the Loan Agreement (the "Previous Announcements").

The board of directors (the "Board" of the "Directors") of China Medical (International) Group Limited (the "Company" and together with its subsidiaries, the "Group") refers to the Previous Announcements and wishes to announce that the Company's wholly own subsidiary, CMIC Hemodialysis (Hong Kong) Limited (the "Subsidiary") has on 27 June 2017 entered into a third supplemental agreement (the "Third Supplemental Agreement") with Concorde Global Limited (the "Lender") to amend and supplement the Loan Agreement, the Supplemental Agreement and the Second Supplemental Agreement.

Pursuant to the Third Supplemental Agreement, it was agreed, *inter alia*, that the Maturity Date (as defined below) be extended to 27 December 2017 and that the Subsidiary shall pay to the Lender interest on the Outstanding Amount (as defined below) at a rate of 14.0% per annum (instead of 12% per annum) from the date of the Third Supplemental Agreement until the Outstanding Amount is repaid in full.

As at the date of the Third Supplemental Agreement, there is an outstanding amount of HK\$20,177,534.25 (equivalent to S\$3,587,565.59⁽¹⁾) (amount inclusive of accrued interest) due from the Subsidiary to the Lender (the "Outstanding Amount") which will be due on 27 June 2017 ("Maturity Date").

Except as to the extent varied or amended by the provisions of the Third Supplemental Agreement, the terms and conditions of the Loan Agreement, the Supplemental Agreement and the Second Supplemental Agreement shall remain in full force and effect.

As announced on 7 June 2017, the Company is currently proposing a renounceable non-underwritten rights issue to raise funds for the purposes of, *inter alia*, repaying its abovementioned outstanding loan obligations.

Note:

- (1) The exchange rate of HKD100.00: S\$17.78 as at 27 June 2017 was used for the conversion. The exchange rate has been extracted from information published by the Monetary Authority of Singapore.

BY ORDER OF THE BOARD

27 June 2017

This announcement has been prepared by the Company and its contents have been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor") for compliance with the Singapore Exchange Securities Trading Limited (the "SGX-ST") Listing Manual Section B: Rules of Catalyst. The Sponsor has not verified the contents of this announcement.

This announcement has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this announcement, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr Lance Tan, Director, Continuing Sponsorship, at 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, telephone (65) 6229 8088.